Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Bosutinib Capsules and Food Effect Study
NCT05032690Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bosutinib in chronic myeloid leukemia (CML) (3 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration-time Curve From Time 0 to Infinity and Maximum Observed Plasma Concentration. Started Jan 2022; status: completed.
02
Drugs
bosutinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05032690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032690.